Web Analytics
Did Kennametal’s (KMT) 5.800% Bond Deal and Tungsten Integration Just Reframe Its Investment Narrative? | Deepscope News
MARKET

Select Market Data Region

 May 25, 2026 09:06 AM  finance.yahoo.com Positive

Did Kennametal’s (KMT) 5.800% Bond Deal and Tungsten Integration Just Reframe Its Investment Narrative?

Image

Kennametal Inc. recently completed a US$298.94 million fixed-income offering of 5.800% senior unsecured notes due May 28, 2036, issued at 99.648% of face value with callable features. The bond deal comes as Kennametal’s vertically integrated tungsten mining and recycling capabilities are helping it win enduring customer relationships during a period of raw material disruption. We’ll now examine how this bond issuance, alongside Kennametal’s tungsten vertical integration, may reshape the company’s broader investment narrative.

Find 48 companies with promising cash flow potential yet trading below their fair value.

Kennametal Investment Narrative Recap

To own Kennametal, you need to believe its tungsten vertical integration and tooling portfolio can translate into durable share gains and better margins, despite uneven end markets. The new US$298.94 million bond adds fixed debt but does not obviously change the near term catalyst, which still centers on converting recent sales momentum into sustainable earnings, or the key risk that structurally weak demand and cost issues could keep revenue and margins under pressure.

The most relevant recent announcement alongside this bond deal is Kennametal’s raised full year 2026 sales guidance to US$2.33–2.35 billion following strong Q3 results. That guidance, underpinned by higher sales and improved net income, sits against earlier concerns about slow organic growth and low returns on capital. How well Kennametal uses the proceeds from this bond in combination with its tungsten advantage will matter for whether that upgraded outlook proves durable.

But even with these positives, investors should be aware that prolonged revenue stagnation near US$2 billion and unresolved cost issues could still...

Read the full narrative on Kennametal (it's free!)

Kennametal's narrative projects $2.6 billion revenue and $254.7 million earnings by 2029. This requires 8.8% yearly revenue growth and about a $144 million earnings increase from $110.3 million today.

Uncover how Kennametal's forecasts yield a $37.57 fair value, a 4% upside to its current price.

Exploring Other PerspectivesKMT 1-Year Stock Price Chart

Before this bond, the most bearish analysts were assuming only about 3.2 percent annual revenue growth to roughly US$2.2 billion and earnings of about US$108 million, so compared with the tungsten driven supply advantage they painted a much harsher risk picture that is worth weighing against this new information.

Explore 3 other fair value estimates on Kennametal - why the stock might be worth 37% less than the current price!

Story Continues

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

A great starting point for your Kennametal research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. Our free Kennametal research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Kennametal's overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource. AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include KMT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments

Read original source